Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Endocrine Gland Neoplasms

ClinicalTrials.gov lists 8,825 trials for Endocrine Gland Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 347.

MeSH D004701 Neoplasms Neoplasm C04 C19
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,597 Phase 1/2 Phase 1/2 723 Phase 2 Phase 2 2,070 Phase 2/3 Phase 2/3 90 Phase 3 Phase 3 529 Phase 4 Phase 4 140 Not applicable Not applicable 1,704 Observational Observational 1,945 Phase 1 Phase 1 1,597 Phase 1/2 Phase 1/2 723 Phase 2 Phase 2 2,070 Phase 2/3 Phase 2/3 90 Phase 3 Phase 3 529 Phase 4 Phase 4 140 Not applicable Not applicable 1,704 Observational Observational 1,945

Trials per phase (log scale)

1 more section with rows

49 of the 8,825 trials are tagged with Endocrine Gland Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Endocrine Gland Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Endocrine Gland Neoplasms trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 21 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 528

1990: 4 trials (Observational 2, Not applicable 1, Phase 1/2 1) 1991: 11 trials (Observational 2, Phase 3 1, Phase 2 5, Phase 1 3) 1992: 7 trials (Observational 4, Phase 2 1, Phase 1 2) 1993: 9 trials (Observational 1, Not applicable 2, Phase 2 6) 1994: 15 trials (Observational 5, Phase 3 3, Phase 2 1, Phase 1/2 2, Phase 1 4) 1995: 17 trials (Observational 5, Phase 4 1, Phase 3 2, Phase 2 7, Phase 1 2) 1996: 25 trials (Observational 3, Phase 3 6, Phase 2 9, Phase 1/2 1, Phase 1 6) 1997: 41 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 4, Phase 2 14, Phase 1/2 6, Phase 1 11) 1998: 66 trials (Observational 3, Not applicable 2, Phase 3 12, Phase 2/3 1, Phase 2 26, Phase 1 22) 1999: 86 trials (Observational 10, Not applicable 2, Phase 3 14, Phase 2/3 1, Phase 2 42, Phase 1/2 2, Phase 1 15) 2000: 79 trials (Observational 15, Not applicable 4, Phase 3 8, Phase 2/3 1, Phase 2 22, Phase 1/2 6, Phase 1 23) 2001: 97 trials (Observational 12, Not applicable 7, Phase 4 3, Phase 3 15, Phase 2 37, Phase 1/2 5, Phase 1 18) 2002: 107 trials (Observational 19, Not applicable 8, Phase 4 3, Phase 3 13, Phase 2/3 1, Phase 2 44, Phase 1/2 4, Phase 1 15) 2003: 142 trials (Observational 18, Not applicable 9, Phase 4 2, Phase 3 13, Phase 2/3 3, Phase 2 70, Phase 1/2 11, Phase 1 16) 2004: 174 trials (Observational 24, Not applicable 15, Phase 4 3, Phase 3 14, Phase 2/3 3, Phase 2 71, Phase 1/2 13, Phase 1 31) 2005: 171 trials (Observational 23, Not applicable 16, Phase 4 1, Phase 3 10, Phase 2/3 4, Phase 2 73, Phase 1/2 13, Phase 1 31) 2006: 238 trials (Observational 36, Not applicable 23, Phase 4 6, Phase 3 20, Phase 2/3 5, Phase 2 100, Phase 1/2 13, Phase 1 35) 2007: 245 trials (Observational 45, Not applicable 17, Phase 4 3, Phase 3 18, Phase 2/3 2, Phase 2 88, Phase 1/2 17, Phase 1 55) 2008: 225 trials (Observational 45, Not applicable 25, Phase 4 5, Phase 3 15, Phase 2 74, Phase 1/2 18, Phase 1 43) 2009: 230 trials (Observational 39, Not applicable 29, Phase 4 2, Phase 3 19, Phase 2/3 4, Phase 2 69, Phase 1/2 24, Phase 1 44) 2010: 260 trials (Observational 51, Not applicable 45, Phase 4 6, Phase 3 14, Phase 2/3 6, Phase 2 76, Phase 1/2 17, Phase 1 45) 2011: 272 trials (Observational 56, Not applicable 49, Phase 4 3, Phase 3 17, Phase 2/3 3, Phase 2 64, Phase 1/2 15, Phase 1 65) 2012: 250 trials (Observational 51, Not applicable 60, Phase 4 7, Phase 3 13, Phase 2/3 3, Phase 2 53, Phase 1/2 23, Phase 1 40) 2013: 284 trials (Observational 59, Not applicable 51, Phase 4 10, Phase 3 14, Phase 2/3 1, Phase 2 68, Phase 1/2 17, Phase 1 64) 2014: 289 trials (Observational 55, Not applicable 70, Phase 4 5, Phase 3 15, Phase 2/3 4, Phase 2 57, Phase 1/2 24, Phase 1 59) 2015: 349 trials (Observational 84, Not applicable 75, Phase 4 4, Phase 3 26, Phase 2/3 2, Phase 2 66, Phase 1/2 26, Phase 1 66) 2016: 401 trials (Other 1, Observational 93, Not applicable 104, Phase 4 7, Phase 3 15, Phase 2/3 4, Phase 2 71, Phase 1/2 35, Phase 1 71) 2017: 403 trials (Observational 85, Not applicable 86, Phase 4 4, Phase 3 14, Phase 2/3 3, Phase 2 87, Phase 1/2 47, Phase 1 77) 2018: 404 trials (Observational 91, Not applicable 88, Phase 4 13, Phase 3 29, Phase 2/3 3, Phase 2 80, Phase 1/2 33, Phase 1 67) 2019: 421 trials (Observational 114, Not applicable 87, Phase 4 8, Phase 3 21, Phase 2/3 2, Phase 2 75, Phase 1/2 34, Phase 1 80) 2020: 459 trials (Observational 112, Not applicable 127, Phase 4 7, Phase 3 20, Phase 2/3 3, Phase 2 89, Phase 1/2 33, Phase 1 68) 2021: 510 trials (Observational 131, Not applicable 113, Phase 4 7, Phase 3 22, Phase 2/3 2, Phase 2 80, Phase 1/2 51, Phase 1 104) 2022: 528 trials (Observational 164, Not applicable 125, Phase 4 5, Phase 3 17, Phase 2/3 1, Phase 2 82, Phase 1/2 39, Phase 1 95) 2023: 459 trials (Observational 116, Not applicable 123, Phase 4 4, Phase 3 13, Phase 2/3 5, Phase 2 84, Phase 1/2 39, Phase 1 75) 2024: 520 trials (Observational 150, Not applicable 94, Phase 4 6, Phase 3 18, Phase 2/3 11, Phase 2 104, Phase 1/2 46, Phase 1 91) 2025: 475 trials (Observational 113, Not applicable 116, Phase 4 6, Phase 3 32, Phase 2/3 7, Phase 2 86, Phase 1/2 50, Phase 1 65)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 453
2025 475
2024 520
2023 459
2022 528
2021 510
2020 459
2019 421
2018 404
2017 403

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 560 trials starting in 2026 and about 500 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 10 percent and ran about 4 percent high against the count later registered; forecasts made before the year began were off by about 25 percent and ran about 15 percent low against the count later registered, and had about 7 percent more error than repeating last year's count. The part-way figures are from forecasts that used a multiple fitted only on earlier years. A stricter check that trains only on older years did not support adding planned starts for conditions of this size: it ran about 6 percent high against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 1,085 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 4,859 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Endocrine Gland Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,597
Phase 1/2 723
Phase 2 2,070
Phase 2/3 90
Phase 3 529
Phase 4 140
Not applicable 1,704
Observational 1,945
Expanded access 27

How many Endocrine Gland Neoplasms trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 404
Recruiting 1,384
Enrolling by invitation 42
Active, not recruiting 542
Available 9

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Endocrine Gland Neoplasms trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 347
Gynecologic Oncology Group 76
AstraZeneca 71
Eli Lilly and Company 56

Which drugs are being tested for Endocrine Gland Neoplasms? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
(nab)-paclitaxel 361
NAB paclitaxel 213
PEMBROLIZUMAB 166
OXALIPLATIN 140
Cytoxan 137

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Gemcitabine/Gemzar 652
or carboplatin 337
Bevacizumab 1 237
Cisplatin 1 174
Fluorouracile 149

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Endocrine Gland Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Vomiting 2,131 466
Abdominal pain 1,895 383
Nausea 1,651 431
Pneumonia 1,627 260
Pyrexia 1,464 241

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Endocrine Gland Neoplasms? (10)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. Frontiers in endocrinology 2021 Yes
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC cancer 2014 Yes
Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocrine-related cancer 2011 Yes
The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocrine reviews 2010 Yes
Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology 2009 Yes

Showing 5 of 10 publications.

Start your 14-day trial Email me all 10 publications as a PDF

Prevalence (4)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Tumor of endocrine glands Annual incidence 1-9 / 100 000 Europe Not stated Exact
Tumor of endocrine glands Annual incidence 1-9 / 100 000 Europe Not stated Exact
Tumor of endocrine glands Point prevalence 6-9 / 10 000 Europe Not stated Exact
Tumor of endocrine glands Point prevalence 6-9 / 10 000 Europe Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Tumor of endocrine glands 182130 Exact Orphanet Rare Disease Ontology (ORDO)
Tumor of endocrine glands 182130 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (9)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages